Residual risk for clinically significant copy number variants in low-risk pregnancies, following exclusion of noninvasive prenatal screening–detectable findings-Reference-Cited by-同舟云学术

Residual risk for clinically significant copy number variants in low-risk pregnancies, following exclusion of noninvasive prenatal screening–detectable findings

Published:2021-11 Issue: Volume: Page:
ISSN:0002-9378
Container-title:American Journal of Obstetrics and Gynecology
language:en
Short-container-title:American Journal of Obstetrics and Gynecology

Author:

Maya Idit,Salzer Sheelo Liat,Brabbing-Goldstein Dana,Matar Reut,Kahana Sarit,Agmon-Fishman Ifaat,Klein Cochava,Gurevitch Merav,Basel-Salmon Lina,Sagi-Dain Lena^ORCID

Publisher

Elsevier BV

Subject

Obstetrics and Gynecology

Reference25 articles.

1. Chromosomal microarray vs. NIPS: analysis of 5541 low-risk pregnancies;Sagi-Dain;Genet Med,2019

2. Screening for fetal chromosomal abnormalities: ACOG Practice Bulletin, Number 226;Obstet Gynecol,2020

3. Facilitating informed choice about non-invasive prenatal testing (NIPT): a systematic review and qualitative meta-synthesis of women’s experiences;Cernat;BMC Pregnancy Childbirth,2019

4. Association of combined first-trimester screen and noninvasive prenatal testing on diagnostic procedures;Larion;Obstet Gynecol,2014

5. Expanded noninvasive prenatal testing for fetal aneuploidy and copy number variations and parental willingness for invasive diagnosis in a cohort of 18,516 cases;Ge;BMC Med Genomics,2021

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. First-Trimester Ultrasound Screening in Routine Obstetric Practice;Obstetrics & Gynecology;2024-06

2. The Diagnostic Yield of Chromosomal Microarray Analysis in Third-Trimester Fetal Abnormalities;American Journal of Perinatology;2024-04-30

3. Prenatal Screening and Diagnosis: Time for a Paradigm Shift;American Journal of Perinatology;2024-04-24

4. Empowering informed choices: revisiting the discussion on prenatal genetic testing in all pregnancies;American Journal of Obstetrics & Gynecology MFM;2024-01

5. Is Nuchal Translucency of 3.0–3.4 mm an Indication for cfDNA Testing or Microarray? – A Multicenter Retrospective Clinical Cohort Study;Fetal Diagnosis and Therapy;2024